# A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)

> **NCT07300111** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Anaemia

## Interventions

- **DRUG:** Daprodustat
- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT07300111
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2027-05
- **Final completion:** 2027-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07300111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07300111, "A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07300111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*